Date: 2011-12-15
Type of information: Collaboration agreement
Compound:
Company: Shire (UK-USA) Atlas Venture (USA)
Therapeutic area: Rare diseases
Type agreement: collaboration
Action mechanism:
Disease:
Details: * On December 15, 2011, Atlas Venture has entered into a multi-year collaboration with Shire Human Genetic Therapies (Shire) to explore investment opportunities in early-stage rare disease therapeutics. Shire and Atlas will work together to identify strategic investments for early stage venture creation around rare genetic diseases. The partnership leverages Shire’s capabilities and knowledge in the research and development of rare diseases with Atlas’ expertise in the formation and growth of early stage companies.
This alliance structure provides an opportunity early in the venture process to utilize all of Shires capabilities in rare diseases from research to commercialization, while leveraging the extensive Atlas network and experience in company formation. Under the agreement, professionals from both Shire and Atlas will be dedicated to work closely together to advance the collaboration effort. Additional terms of the agreement are not being disclosed.
Financial terms:
Latest news: * On May 8, 2013, Shire has announced the first deal concluded through its strategic with Atlas Venture. The group has signed a co-development agreement withNimbus Discovery focused on small molecule treatments for lysosomal storage disorders.
